CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions Novel functions of macrophages in the heart: insights into electrical conduction, stress, and diastolic dysfunction Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization Routine Continuous Electrocardiographic Monitoring Following Percutaneous Coronary Interventions State of the Art in Noninvasive Imaging of Ischemic Heart Disease and Coronary Microvascular Dysfunction in Women: Indications, Performance, and Limitations Rare Genetic Variants Associated With Sudden Cardiac Death in Adults Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications Invasive Coronary Physiology After Stent Implantation: Another Step Toward Precision Medicine Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention

Review ArticleVolume 76, Issue 4, July 2020

JOURNAL:J Am Coll Cardiol. Article Link

Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review

G Marquis-Gravel, DJ Moliterno, SG Goodman et al. Keywords: PCI; trail design; SCAD

ABSTRACT

The role of percutaneous coronary interventions in addition to medical therapy for patients with stable coronary artery disease continues to be debated in routine clinical practice, despite more than 2 decades of randomized controlled trials. The residual uncertainty arises from particular challenges facing revascularization trials. Which endpoint do doctors care about, and which do patients care about? Which participants should be enrolled? What background medical therapy should we use? When is placebo control relevant? In this paper, we discuss how these questions can be approached and examine the merits and disadvantages of possible options. Engaging multiple stakeholders, including patients, researchers, regulators, and funders, to ensure the design elements are methodologically valid and clinically meaningful should be an aspirational goal in the development of future trials.